If you’re a biotech or medtech founder trying to figure out where non-dilutive funding stands right now, this is your mid-year briefing.

The first half of 2026 was the most disruptive period for federal small business innovation funding in the program’s 43-year history. A six-month lapse. A legislative restart. The largest new award mechanism ever created. Record-low success rates at NIH. A $1.27 billion CDMRP round. And a venture capital environment that’s quietly making non-dilutive funding more critical than ever.

We pulled the numbers from NIH RePORTER, SBIR.gov, federal appropriations data, and industry reports to give you the full picture; what happened, where things stand, and what it means for your funding strategy through the rest of 2026.

The Six-Month Lapse: What It Cost

On September 30, 2025, Congress let the SBIR/STTR programs expire. For six months, until April 13, 2026, when President Trump signed S. 3971 into law, the pipeline was frozen. No new solicitations. No new awards. No new Phase I entry points for first-time applicants.

The numbers tell the story of the damage:

• ~1,984 lost awards — the gap between the FY2020–2024 annual average of 6,713 awards and the 4,729 actually made in FY2025
• ~$490 million in funding that never reached small businesses
• Phase I awards fell by ~1,571 compared to the five-year baseline, a 32% drop from the prior year’s 3,811
• More than 1,500 research projects that never got off the ground at the average Phase I award size of $197,000

The asymmetry matters. Phase I is where new companies and new technologies enter the program. A 32% drop means thousands of small firms never received a first federal contract, never generated the data needed to attract private co-investment, and may have moved on to other pursuits entirely. The companies that didn’t get a Phase I in 2025 won’t be eligible for Phase II until they do, creating a compressed pipeline that agencies are still working through.

Source: SBIR.gov award database analysis, FY2020–FY2025. Federal News Network

NIH in 2026: Bigger Budget, Harder Competition

NIH received a $47.2 billion budget for FY2026, a $400 million increase over FY2025. Congress explicitly rejected the administration’s proposed cuts, signaling continued bipartisan support for biomedical research.

As of June 29, 2026, NIH has already awarded $179.9 million in SBIR/STTR funding this fiscal year. New NOFOs were released on May 29, 2026, with the first major deadline on September 5, 2026.

But here’s the catch: competition is fiercer than ever.

NIH Phase I SBIR success rates have been declining for years, from ~17.5% in the early 2010s to ~13% in FY2021 to a record low of 9.9% most recently. Success rates vary dramatically by institute:

• NCI (National Cancer Institute): ~4.3% Phase I success rate
• NIAID (Allergy & Infectious Diseases): similarly low
• NCATS (Translational Science): ~13.2%
• NCCIH (Complementary & Integrative Health): ~13.8%

Translation: if you’re applying to NCI for a Phase I SBIR, you have roughly a 1-in-23 chance. At NCATS, it’s closer to 1-in-8.

The new award sizes help offset the longer odds. Phase I awards now go up to $305,000 (up from ~$275K), and Phase II awards can reach $3 million. For companies with strong science and the right institute match, the payoff per application is larger than ever.

Phase I: Establish the technical merit and feasibility of the proposed R&D, and a budget of $323,090 for a project timeline between 6 months to 2 years.
With institute specific waivers, total funding support can exceed the designated SBA budgetary guidelines, going up to as high as $700,000 for Phase I

Phase II: Continue R&D to advance toward commercialization, and a budget of  $2,153,927 for a project timeline between 1 to 3 years.
With institute specific waivers, total funding support can exceed the designated SBA budgetary guidelines, going up to as high as $3,000,000 for Phase II

NIH Fast-Track: The NIH Fast-Track allows both Phase I and Phase II of a project to be submitted and reviewed together as one application to reduce or eliminate the funding gap between phases.

NIH Direct to Phase II: Small businesses that have already demonstrated scientific and technical merit and feasibility but have not received a Phase I SBIR or STTR for that project, can apply for a Direct to Phase II award.

STTR Equivalent: NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional) – The STTR grant program helps US small business who partner with a nonprofit research institutions bring scientific innovations to the marketplace.

Sources: NIH RePORT, NIH Data Book, NIH Data Book — Success Rates, Congressional budget reporting

The Strategic Breakthrough Award: Up to $30 Million to Bridge the Valley of Death

The single most significant change in the SBIR/STTR reauthorization is the creation of Strategic Breakthrough Awards, a post-Phase II funding mechanism that can provide up to $30 million to a single small business over 48 months.

This has never existed before. Traditional Phase II awards cap at $750K–$3M. The gap between a successful Phase II prototype and a commercially viable product, the “valley of death”, has been the SBIR program’s most persistent failure mode for four decades. Strategic Breakthrough Awards are designed to bridge it.

Key facts:

• Award size: With institute specific waivers, total funding ranges between $3,000,000 – $15,000,000!
• Performance period: Maximum 48 months
• Matching requirement: 100% matching funds from new private capital or qualifying non-SBIR government sources
• Eligibility: Must hold at least one prior Phase II SBIR or STTR award
• Eligible agencies: DoD, NIH, NSF (agencies with >$100M annual SBIR obligations)
• Timeline: DoD expected to move first (July–September 2026); most other agencies in FY2027

The matching funds requirement is the critical gate. The statute specifies that matching funds must be “new private capital as a result of” the Strategic Breakthrough Award, meaning capital already raised before you apply likely does not qualify. If you’re in discussions with investors, the timing of any investment relative to your application matters. Work with legal counsel to structure the investment so it clearly satisfies the matching requirement.

For DoD-specific Strategic Breakthrough Awards, at least 20% of matching funds must come from new DoD funding outside of SBIR/STTR programs. The technology must also have a commitment for inclusion in a Program Objective Memorandum (POM) from a senior acquisition official, a significant bar.

Sources: S. 3971, SBIR Grant Writers, NIH SEED

CDMRP: $1.27 Billion Across 34 Programs

The Congressionally Directed Medical Research Programs (CDMRP) announced one of its largest funding years on record for FY2026: $1.27 billion across 34 research programs.

CDMRP is one of the most underutilized non-dilutive funding sources in the life science ecosystem. Managed by the Department of Defense, it funds disease-specific research across cancer, neurology, autoimmune diseases, rare diseases, and military health. The full list of 34 active programs includes:

• Cancer programs: Breast Cancer, Kidney Cancer, Lung Cancer, Melanoma, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Peer Reviewed Cancer, Rare Cancers
• Neurological: Alzheimer’s, ALS, Autism, Epilepsy, Multiple Sclerosis, Neurofibromatosis, Parkinson’s, TBI and Psychological Health, Tuberous Sclerosis
• Autoimmune & immune: Arthritis, Lupus, Bone Marrow Failure, Tick-Borne Disease
• Military health: Combat Readiness-Medical, Joint Warfighter Medical, Military Burn, Orthopaedic, Toxic Exposures, Vision, Hearing Restoration
• Other: Alcohol and Substance Use Disorders, Duchenne Muscular Dystrophy, Reconstructive Transplant Research, Spinal Cord Injury

What makes CDMRP different from NIH: it uses a two-tier review process that includes both scientific peers and consumer reviewers — patient advocates who evaluate the real-world impact of the proposed research. Applications must speak to the human impact, not just the science. This is a critical differentiator that most applicants miss.

Deadlines are staggered by program through July–November 2026. The Peer Reviewed Medical Research Program (PRMRP), one of the broadest programs, has a letter of intent deadline of July 16, 2026.

Source: CDMRP FY2026 Appropriations Announcement

The Venture Capital Backdrop: Why Non-Dilutive Matters More Now

The case for non-dilutive funding has never been stronger and the venture capital data explains why.

Global biotech VC investment reached approximately $38 billion in 2025, a 28% increase over 2024’s $29.7 billion. But that headline number masks a dangerous trend: early-stage biotech funding in 2026 is slumping toward its worst year since before the pandemic. First-time biotech financings are on course for a post-pandemic low.

Meanwhile, the demand side is shifting:

• 38% of seed-stage biotech companies now plan to make non-dilutive funding a core part of their strategy, a significant increase
• 41% of biotech companies expect to seek additional funding for R&D in 2026, up from just 14% the year before
• The “valley of death” between Phase II completion and commercialization remains the most dangerous gap in biotech funding

Translation: more companies are chasing the same pool of early-stage venture dollars, and those dollars are getting harder to secure. Non-dilutive funding, particularly SBIR/STTR with the new Strategic Breakthrough Award pathway, is becoming the strategic differentiator that separates companies that survive the valley of death from those that don’t.

Sources: BioSpace, FierceBiotech, BioPharma Dive

The Other Agencies: BARDA, ARPA-H, NSF

BARDA (Biomedical Advanced Research & Development Authority)

BARDA’s DRIVe initiative continues to accept rolling applications through the EZ-BAA mechanism for awards under $750K, with larger advanced development contracts ranging from $1M to $100M+. BARDA is mission-driven, your technology must address national health security priorities: pandemic preparedness, biological threats, chemical/radiological exposures. Select programs have a priority deadline of September 1, 2026.

Source: BARDA DRIVe

ARPA-H (Advanced Research Projects Agency for Health)

Modeled on DARPA, ARPA-H funds transformative, high-risk biomedical innovation. Program managers make personal bets on people as much as on science: relationship-building before submitting is strongly recommended. ARPA-H had a major presence at BIO 2026 in June. The SBIR program has a solution summary deadline of July 10, 2026, and the IGoR program (AI-driven biomedical R&D) is accepting rolling submissions.

Source: ARPA-H Open Funding Opportunities

NSF (National Science Foundation)

NSF SBIR funds deep tech and platform technologies, synthetic biology, AI/ML in health, novel materials, computational tools. Phase I awards go up to $275K; Phase II up to $1M. NSF requires a Project Pitch before a full proposal. Next full proposal deadlines: July 27, 2026 and November 4, 2026.

Source: NSF SBIR Full Proposal

What This Means for Your Strategy

The 2026 non-dilutive funding landscape is defined by three forces: disruption, opportunity, and urgency.

The disruption is behind us! The SBIR/STTR programs are reauthorized through 2031, and the pipeline is reopening. But the backlog means agencies are processing compressed queues of applications from companies at varying stages of readiness. The companies that are prepared now will have a window advantage over those still catching up.

The opportunity is unprecedented: the Strategic Breakthrough Award creates a pathway that didn’t exist before. CDMRP has $1.27B available. NIH award sizes are larger. ARPA-H is actively funding. The total addressable non-dilutive funding pool for life science companies in 2026 is likely the largest it has ever been.

The urgency is real! The September 5 NIH deadline is 10 weeks away. NSF’s July 27 deadline is even closer. CDMRP’s PRMRP LOI is due July 16. If you haven’t started your application yet, you’re already behind.

Three things to do this week:

1. Audit your agency fit. Are you targeting the right agency for your technology’s stage, indication, and commercialization pathway? The data shows that success rates vary by a factor of 3x between NIH institutes — agency selection is not a detail, it’s a strategy.
2. If you have a Phase II award, evaluate Strategic Breakthrough eligibility. The matching funds requirement is complex but navigable. This is a once-in-a-generation funding mechanism, and most companies don’t understand it yet — which means less competition for those who move early.
3. Don’t overlook CDMRP. $1.27 billion across 34 programs is one of the most underutilized funding pools in life science. If your indication overlaps with any of CDMRP’s programs — and many do — the PRMRP LOI deadline is July 16.

FreeMind Group helps life science companies build non-dilutive funding strategies, not just write applications. Right agency, right mechanism, right timeline. If you want to talk through what your strategy should look like for the rest of 2026, book a free consultation.